7种注射剂型脑细胞保护剂治疗缺血性脑卒中的临床综合评价  

Multidimensional Evaluation of 7 Kinds of Injectable Brain Cytoprotection Agents for Ischemic Stroke

作　　者：魏安华 王璐 曾露[1] 刘东[1] 贡雪芃 WEI Anhua;WANG Lu;ZENG Lu;LIU Dong;GONG Xuepeng(Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院药学部,武汉430030

出　　处：《医药导报》2025年第5期778-786,共9页Herald of Medicine

摘　　要：目的对治疗缺血性脑卒中的脑细胞保护剂进行多维度评价,为临床用药及医疗机构遴选药物提供参考。方法基于《中国医疗机构药品评价与遴选快速指南(第二版)》评价体系,对部分评分细则进行调整,并参考药品说明书、临床指南及中国国家知识基础设施、万方数据库、维普中文科技期刊数据库、PubMed、Embase、Cochrane Library等数据库相关文献,从药学特性、有效性、安全性、经济性,以及其他属性(医疗保险、基本药物、生产企业等)5个维度对7种注射剂型的脑细胞保护剂进行量化评分。结果纳入评价药物的评分整体偏低,排序前3药物分别为依达拉奉右莰醇注射用浓溶液(63.15分)、人尿激肽原酶注射液(62.20分)和丁苯酞氯化钠注射液(62.04分)。胞磷胆碱钠注射液因有效性不明确评分最低(37.07分)。结论依据指南推荐,依达拉奉右莰醇注射用浓溶液、人尿激肽原酶注射液和丁苯酞氯化钠注射液得分>60分,在医疗机构中无替代药品时弱推荐引进,可为缺血性脑卒中的治疗用药遴选和临床合理用药提供参考。Objective To conduct a multidimensional evaluation of brain cytoprotection agents used in the treatment of ischemic stroke,and to provide an evidence-based basis of medication selection and rational clinical use for medical institutions'decision-makers.Methods Based on the"Quick Guide to Drug Evaluation and Selection for Chinese Medical Institutions(Second Edition)"evaluation system,some scoring rules were adjusted.Referring to drug instructions,clinical guidelines,and relevant literature from databases such as China National Knowledge Infrastructure(CNKI),Wanfang Database,VIP Database for Chinese Technical Periodicals(VIP),Pubmed,Embase,and Cochrane Library,seven brain cytoprotection agents were quantitatively scored from five dimensions:pharmacological characteristics,effectiveness,safety,economic aspects,and other attributes(insurance coverage,essential drugs,manufacturing enterprises).Results Overall,the evaluated drugs received low scores.The top three drugs were edaravone and dexborneol injection(63.15 points),urinary kallidinogenase injection(62.20 points),and butylphthalide injection(62.04 points).Citicoline injection had the lowest score due to unclear effectiveness(37.07 points).Conclusions Based on guideline recommendations,edaravone and dexborneol,urinary kallidinogenase,and butylphthalide,which scored above 60,are weakly recommended when no alternative medications are available in medical institutions.This study can be used as a reference for the selection of therapeutic drugs for ischemic stroke in medical institutions and offer a basis for rational clinical medication use.

关 键 词：脑细胞保护剂 缺血性脑卒中 药品评价 药物遴选 

分 类 号：R971[医药卫生—药品] R969.3[医药卫生—药学]